← Back to Search

Glutamate Receptor Antagonist

Dipraglurant for Parkinson's Disease

Phase 2 & 3
Recruiting
Research Sponsored by Addex Pharma S.A.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline (day 1) to week 12
Awards & highlights

Study Summary

This trial is testing a new drug to see if it's effective and safe for treating dyskinesia in Parkinson's patients. The primary efficacy assessment will be based on the Unified Dyskinesia Rating Scale.

Eligible Conditions
  • Parkinson's Disease
  • Dyskinesia

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline (day 1) to week 12
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline (day 1) to week 12 for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change from baseline on the Unified Dyskinesia Rating Scale (UDysRS) total score
Secondary outcome measures
Change from baseline in OFF time based on a standardized PD diary
Change from baseline in ON time without troublesome dyskinesia based on a standardized PD diary

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: Dipraglurant TIDExperimental Treatment1 Intervention
Group II: Placebo TIDPlacebo Group1 Intervention

Find a Location

Who is running the clinical trial?

Addex Pharma S.A.Lead Sponsor
7 Previous Clinical Trials
1,018 Total Patients Enrolled

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Are there any vacancies open in this clinical trial for new patients?

"Yes, according to the information available on clinicaltrials.gov, this trial is currently looking for participants. The original posting date was 8/6/2021, and the most recent update was 5/18/2022. 41 sites are needed to enroll the 140 desired participants."

Answered by AI

May I enroll in this clinical research study?

"Eligibility criteria for this clinical trial include age (between 30 and 85 years old), diagnosis of dyskinesia, and the cause of dyskinesia being drug-induced. In total, 140 patients will be accepted into the study."

Answered by AI

Does this research project have a presence in multiple states?

"Currently, 41 patients are being recruited for this trial taking place at University of Toledo, Gardner-McMaster Parkinson Center in Toledo, Sentara Neurology Specialists in Virginia Beach and University of New mexico Health Sciences Center in Albuquerque - to name a few other locations."

Answered by AI

Does this research set a precedent?

"As of now, there are two clinical trials in progress for Dipraglurant spanning 41 cities and one nation. The first trial took place in 2021; it was sponsored by Addex Pharma S.A., had 140 participants, and completed both Phase 2 & 3 of the drug approval process. Since then, a total of 18279 have been conducted."

Answered by AI

Is this research project open to people below the age of 20?

"According to the eligibility requirements for this particular trial, applicants must be between 30 and 85 years old. There are 39 clinical trials for patients under 18 and 532 for seniors above 65."

Answered by AI

To what extent has Dipraglurant been studied in other medical trials?

"There are a total of 2 Dipraglurant clinical trials underway, both of which are in their third phase. Although the majority of these trials are based out of one city - Philadelphia, Pennsylvania - there are a total of 48 locations running experiments for this medication."

Answered by AI

Who else is applying?

What state do they live in?
Washington
What site did they apply to?
Evergreen Hospital Medical Center
What portion of applicants met pre-screening criteria?
Met criteria
Recent research and studies
clinicaltrials.govStudy
Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy
2021. "Dipraglurant (ADX48621) for the Treatment of Patients With Parkinson's Disease Receiving Levodopa-based Therapy". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT04857359.
~38 spots leftby Apr 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top